Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […] Read more
Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more
The US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based […] Read more
Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. […] Read more
By Christian Rolfo, MD, PhD, MBA, Dr.h.c. Posted: December 11, 2019 IN REFERENCE TO: Phallen J, Leal A, Woodward BD, et al. Early Noninvasive Detection of Response to Targeted Therapy […] Read more
Improved Turnaround Times for Biopsy Results Matters More Than Type of Biopsy By Dr. Edgardo S. Santos Castillero, MD, FACP Posted: December 11, 2019 Dr. Edgardo S. Santos Castillero Regarding “Liquid Biopsy […] Read more